✦ LIBER ✦

Minimal residual disease, the rationale for adjuvant therapy in epithelial malignancies

✍ Scribed by Aviram Nissan

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 69 KB
Volume: 96
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.20813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Photodynamic therapy using mTHPC for mal

Photodynamic therapy using mTHPC for malignant disease in the oral cavity

✍ Kathleen F.M. Fan; Colin Hopper; Paul M. Speight; Giovanni A. Buonaccorsi; Steph 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 428 KB 👁 1 views

Photodynamic therapy (PDT) produces local tumor necrosis, on activation of a previously administered sensitizer with non-thermal light of an appropriate wavelength. It is attractive for treating tumors of the mouth as tissue healing is particularly good. We describe the use of the photosensitizing a

Detecting of the minimal residual diseas

Detecting of the minimal residual disease contaminated in peripheral blood stem cell transplantation in the B-Cell malignant lymphoma patients

✍ Dr. Masaya Nagasu; Shin Aizawa; Hitoshi Hojo; Akemi Tsuda; Makoto Yaguchi; Masar 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB 👁 3 views

Therapy for minimal residual tumor disea

Therapy for minimal residual tumor disease: β-Galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

✍ Jana Šímová; Marie Indrová; Jana Bieblová; Romana Mikyšková; Jan Bubeník; Milan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 385 KB

## Abstract Natural killer T (NKT) cells are potent modulators of antitumor immunity. Their protective effects can be achieved upon their activation by glycolipid ligands presented in the context of the CD1d molecule. These CD1d‐binding glycolipid antigens have been described as potent therapeutic

Quantitative monitoring of cyclin D1 exp

Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma

✍ Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 235 KB

## Abstract In mantle cell lymphoma (MCL), minimal residual disease (MRD) is an indicator of the disease outcome. Quantitative methods used so far do not provide a suitable molecular marker in 30–70% patients with MCL (depending on the technique used). We tested cyclin D1 as a marker for quantitati

Prospective comparison of two flow cytom

Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia

✍ Drorit Luria; Eti Rosenthal; David Steinberg; Yona Kodman; Marina Safanaiev; Nin 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

The extent of minimal residual disease r

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

✍ Seok Lee; Yoo-Jin Kim; Nak-Gyun Chung; Jihyang Lim; Dong-Gun Lee; Hee-Je Kim; Ch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 2 views

## Abstract ## BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐positive ALL). Here, the authors analyzed for risk factors that af